PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of
PsychoGenics is planning the development of RO7117997 for the treatment of multiple CNS conditions starting with sleep and seizure disordersPARAMUS, N.J.--(BUSINESS WIRE)--PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agre...